PH27037A - Use of catechol-o-methyl transferase (COMT) inhibitors and their physiologically acceptance salts and esters for ulcer treatments - Google Patents
Use of catechol-o-methyl transferase (COMT) inhibitors and their physiologically acceptance salts and esters for ulcer treatments Download PDFInfo
- Publication number
- PH27037A PH27037A PH37972A PH37972A PH27037A PH 27037 A PH27037 A PH 27037A PH 37972 A PH37972 A PH 37972A PH 37972 A PH37972 A PH 37972A PH 27037 A PH27037 A PH 27037A
- Authority
- PH
- Philippines
- Prior art keywords
- compound
- carbon atoms
- cyano
- nitro
- hydrogen
- Prior art date
Links
- 208000025865 Ulcer Diseases 0.000 title claims description 20
- 231100000397 ulcer Toxicity 0.000 title claims description 19
- 150000003839 salts Chemical class 0.000 title claims description 5
- 238000011282 treatment Methods 0.000 title claims description 5
- 150000002148 esters Chemical class 0.000 title claims description 3
- 239000003112 inhibitor Substances 0.000 title description 4
- 102000006378 Catechol O-methyltransferase Human genes 0.000 title 2
- 108020002739 Catechol O-methyltransferase Proteins 0.000 title 2
- 150000001875 compounds Chemical class 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 25
- 230000003902 lesion Effects 0.000 claims description 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- -1 methoxyl groups Chemical group 0.000 claims description 4
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 10
- 125000001589 carboacyl group Chemical group 0.000 claims 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- WDCYWAQPCXBPJA-UHFFFAOYSA-N 1,3-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC([N+]([O-])=O)=C1 WDCYWAQPCXBPJA-UHFFFAOYSA-N 0.000 claims 1
- 241000006460 Cyana Species 0.000 claims 1
- 240000007313 Tilia cordata Species 0.000 claims 1
- 229940125890 compound Ia Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 241000700159 Rattus Species 0.000 description 11
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 229960003151 mercaptamine Drugs 0.000 description 7
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 210000001198 duodenum Anatomy 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 208000000718 duodenal ulcer Diseases 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000008469 Peptic Ulcer Diseases 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 230000002183 duodenal effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- TZMFJUDUGYTVRY-UHFFFAOYSA-N ethyl methyl diketone Natural products CCC(=O)C(C)=O TZMFJUDUGYTVRY-UHFFFAOYSA-N 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 150000005206 1,2-dihydroxybenzenes Chemical class 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 101710116650 FAD-dependent monooxygenase Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 101710128228 O-methyltransferase Proteins 0.000 description 1
- 206010062065 Perforated ulcer Diseases 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005277 alkyl imino group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical class C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid group Chemical group C(CC(=O)O)(=O)O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000013435 necrotic lesion Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- KGPGQDLTDHGEGT-JCIKCJKQSA-N zeven Chemical compound C=1C([C@@H]2C(=O)N[C@H](C(N[C@H](C3=CC(O)=C4)C(=O)NCCCN(C)C)=O)[C@H](O)C5=CC=C(C(=C5)Cl)OC=5C=C6C=C(C=5O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@H](O5)C(O)=O)NC(=O)CCCCCCCCC(C)C)OC5=CC=C(C=C5)C[C@@H]5C(=O)N[C@H](C(N[C@H]6C(=O)N2)=O)C=2C(Cl)=C(O)C=C(C=2)OC=2C(O)=CC=C(C=2)[C@H](C(N5)=O)NC)=CC=C(O)C=1C3=C4O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O KGPGQDLTDHGEGT-JCIKCJKQSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/06—Phenols the aromatic ring being substituted by nitro groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB878730190A GB8730190D0 (en) | 1987-12-24 | 1987-12-24 | New use of catechol-o-methyl transferase(comt)inhibitors & their physiologically acceptable salts & esters |
| GB888820729A GB8820729D0 (en) | 1987-12-24 | 1988-09-01 | Substituted beta-diketones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH27037A true PH27037A (en) | 1993-02-01 |
Family
ID=26293247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH37972A PH27037A (en) | 1987-12-24 | 1988-12-22 | Use of catechol-o-methyl transferase (COMT) inhibitors and their physiologically acceptance salts and esters for ulcer treatments |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5001152A (da) |
| EP (1) | EP0323162B1 (da) |
| JP (1) | JPH02196715A (da) |
| AU (1) | AU617397B2 (da) |
| BE (1) | BE1003759A5 (da) |
| CH (1) | CH683395A5 (da) |
| DE (1) | DE3843324A1 (da) |
| DK (1) | DK713288A (da) |
| ES (1) | ES2059546T3 (da) |
| HU (1) | HU200684B (da) |
| IE (1) | IE883816L (da) |
| IL (1) | IL88734A (da) |
| IT (1) | IT1227914B (da) |
| LU (1) | LU87412A1 (da) |
| MT (1) | MTP1031B (da) |
| PH (1) | PH27037A (da) |
| SE (1) | SE8804608L (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283352A (en) * | 1986-11-28 | 1994-02-01 | Orion-Yhtyma Oy | Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same |
| GB9004348D0 (en) * | 1990-02-27 | 1990-04-25 | Orion Yhtymae Oy | New use of catechol derivatives and their physiologically acceptable salts and esters |
| GB9002337D0 (en) * | 1990-02-02 | 1990-04-04 | Orion Yhtymae Oy | Compounds useful in treating inflammatory bowel disease |
| US5185370A (en) * | 1988-09-01 | 1993-02-09 | Orion-Yhtyma Oy | Substituted β-diketones and their use |
| IL91382A (en) * | 1988-09-01 | 1995-06-29 | Orion Yhtymae Oy | Dicitons are converted into alkanyl or ethylmethylene, through their preparation and pharmaceutical preparations containing them |
| JPH05301838A (ja) * | 1991-10-15 | 1993-11-16 | Mitsubishi Kasei Corp | スチレン誘導体 |
| GB9626472D0 (en) * | 1996-12-20 | 1997-02-05 | Aperia Anita C | New use of comt inhibitors |
| FI981521A0 (fi) | 1998-07-01 | 1998-07-01 | Orion Corp | Substituoidut beta-diketonit ja niiden käyttö |
| FI20000635A0 (fi) * | 2000-03-17 | 2000-03-17 | Orion Yhtymae Oyj | COMT-inhibiittoreiden käyttö analgeettina |
| GB0015228D0 (en) * | 2000-06-21 | 2000-08-16 | Portela & Ca Sa | Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB902586A (en) * | 1960-01-01 | 1962-08-01 | Shell Res Ltd | Herbicidal compositions and novel compounds for use therein |
| GB1188364A (en) * | 1967-05-02 | 1970-04-15 | May & Baker Ltd | Quinoline Derivatives |
| BE759266A (fr) * | 1969-11-24 | 1971-05-24 | Hoffmann La Roche | Procede pour la preparation de derives de l'indole |
| CA1190223A (en) * | 1977-11-01 | 1985-07-09 | Anthony C. Richardson | Substrates for enzymes |
| FR2504004A1 (fr) * | 1981-04-17 | 1982-10-22 | Roussel Uclaf | Application a titre de medicaments de derives d'acides phenyl aliphatique carboxyliques |
| JPS5890534A (ja) * | 1981-11-25 | 1983-05-30 | Ono Pharmaceut Co Ltd | ２−アミノフエノ−ル誘導体、その製造方法およびその誘導体を有効成分として含有する治療剤 |
| SU1424729A3 (ru) * | 1983-05-13 | 1988-09-15 | Яманоути Фармасьютикал Ко,Лтд (Фирма) | Способ получени производных катехина |
| FR2557098B1 (fr) * | 1983-12-22 | 1986-06-13 | Rhone Poulenc Spec Chim | Procede de preparation de bromobenzaldehydes hydroxy et/ou alkoxy substitues |
| FR2557097B1 (fr) * | 1983-12-22 | 1986-06-13 | Rhone Poulenc Spec Chim | Procede de preparation de bromobenzaldehydes hydroxy et/ou alkoxy substitues |
| US4760089A (en) * | 1985-09-09 | 1988-07-26 | Smithkline Beckman Corporation | Irreversible dopamine-β-hydroxylase inhibitors |
| DK175069B1 (da) * | 1986-03-11 | 2004-05-24 | Hoffmann La Roche | Pyrocatecholderivater |
| YU213587A (en) * | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
| DK49688A (da) * | 1987-03-20 | 1988-09-21 | Hoffmann La Roche | Propiolophenonderivater |
-
1988
- 1988-12-16 MT MT1031A patent/MTP1031B/xx unknown
- 1988-12-20 IL IL8873488A patent/IL88734A/en not_active IP Right Cessation
- 1988-12-21 DK DK713288A patent/DK713288A/da not_active Application Discontinuation
- 1988-12-21 SE SE8804608A patent/SE8804608L/xx not_active Application Discontinuation
- 1988-12-21 IE IE883816A patent/IE883816L/xx unknown
- 1988-12-22 EP EP88312228A patent/EP0323162B1/en not_active Expired - Lifetime
- 1988-12-22 ES ES88312228T patent/ES2059546T3/es not_active Expired - Lifetime
- 1988-12-22 CH CH4750/88A patent/CH683395A5/de not_active IP Right Cessation
- 1988-12-22 DE DE3843324A patent/DE3843324A1/de not_active Withdrawn
- 1988-12-22 PH PH37972A patent/PH27037A/en unknown
- 1988-12-22 LU LU87412A patent/LU87412A1/fr unknown
- 1988-12-23 HU HU886594A patent/HU200684B/hu not_active IP Right Cessation
- 1988-12-23 JP JP63327515A patent/JPH02196715A/ja active Pending
- 1988-12-23 AU AU27459/88A patent/AU617397B2/en not_active Ceased
- 1988-12-23 IT IT8823107A patent/IT1227914B/it active
- 1988-12-23 US US07/288,979 patent/US5001152A/en not_active Expired - Fee Related
- 1988-12-23 BE BE8801433A patent/BE1003759A5/fr not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU617397B2 (en) | 1991-11-28 |
| LU87412A1 (fr) | 1989-06-14 |
| IL88734A0 (en) | 1989-07-31 |
| BE1003759A5 (fr) | 1992-06-09 |
| IT8823107A0 (it) | 1988-12-23 |
| DK713288A (da) | 1989-06-25 |
| SE8804608D0 (sv) | 1988-12-21 |
| EP0323162B1 (en) | 1993-09-15 |
| EP0323162A3 (en) | 1990-11-14 |
| IE883816L (en) | 1989-06-24 |
| IT1227914B (it) | 1991-05-14 |
| SE8804608L (sv) | 1989-06-25 |
| MTP1031B (en) | 1990-10-04 |
| AU2745988A (en) | 1989-06-29 |
| DE3843324A1 (de) | 1989-07-06 |
| EP0323162A2 (en) | 1989-07-05 |
| JPH02196715A (ja) | 1990-08-03 |
| US5001152A (en) | 1991-03-19 |
| HU200684B (en) | 1990-08-28 |
| ES2059546T3 (es) | 1994-11-16 |
| DK713288D0 (da) | 1988-12-21 |
| IL88734A (en) | 1994-01-25 |
| CH683395A5 (de) | 1994-03-15 |
| HUT49053A (en) | 1989-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0160008B2 (da) | ||
| PH27037A (en) | Use of catechol-o-methyl transferase (COMT) inhibitors and their physiologically acceptance salts and esters for ulcer treatments | |
| RO115780B1 (ro) | Combinatie sinergica | |
| JPS61197517A (ja) | 薬剤組成物 | |
| DE69302646T2 (de) | Benzimidazolverbindungen als Antibiotika gegen Campylobacter pylon | |
| Satoh et al. | Proton pump inhibitors prevent gastric antral ulcers induced by NSAIDs via activation of capsaicin-sensitive afferent nerves in mice | |
| US20070292535A1 (en) | Strontium compositions and methods of treating arthritic and or osteoporitic conditions | |
| Sontag | Guilty as charged: bugs and drugs in gastric ulcer. | |
| IE85899B1 (en) | New oral drug forms | |
| McQuaid et al. | Medical therapy of peptic ulcer disease | |
| US3681497A (en) | Therapeutic methods of employing hydrogen maleate salt of n-(d-6-methyl-8-isoergolenyl)-n{40 ,n{40 -diethyl-carbamide | |
| KR20010024050A (ko) | 항균제 | |
| Ballinger | Cytoprotection with misoprostol: use in the treatment and prevention of ulcers | |
| JP3452922B2 (ja) | 平滑筋臓器の緊張を増加するため、および緊張を調節するための植物ベースの医薬 | |
| EP0017169B1 (en) | Improved anti-inflammatory combinations having reduced ulcerogenicity | |
| JP3680950B2 (ja) | アリルアミンの用途 | |
| JPS615017A (ja) | 抗潰瘍組成物 | |
| US20050054577A1 (en) | Compositions for treating digestive functional pathologies | |
| CN112933091B (zh) | 一种抗胃酸类疾病的药物组合物及应用 | |
| DE69529981T2 (de) | Verwendung von spiramyeine in von h.pylori verursachten magen und darm beschwerden | |
| CN102920705A (zh) | 泰妥拉唑在制造治疗胃食管反流性疾病的药物中的应用 | |
| JPH0250883B2 (da) | ||
| US4622316A (en) | 13-thiaprostaglandins having cytoprotective activity | |
| KR102619907B1 (ko) | 가축설사 치료용 복합제 조성물 | |
| Lambert | Proton pump inhibitors: over-the-counter management of acid reflux |